Focal-onset or partial seizures are limited to one area of the brain and are the most common form of seizures in adults. Focal-onset seizures can last up to two minutes and can involve involuntary movements and be associated with impaired awareness.
More than 45 million people live with active epilepsy worldwide, with more than half of those living with focal seizures.
NBI-921352: An Investigational Therapy for Focal-Onset Seizures
NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed to treat adults with focal-onset seizures.
Neurocrine Biosciences acquired the exclusive rights to NBI-921352 from Xenon Pharmaceuticals.
Neurocrine Biosciences is also developing NBI-921352 for the potential treatment of SCN8A-DEE.
Clinical Trials: Focal-Onset Seizures
Neurocrine Biosciences is currently conducting a Phase 2 study of NBI-921352 in patients with focal-onset seizures.